Antisense oligonucleotide therapeutics for human leukemia

被引:3
作者
Gewirtz, AM
机构
[1] Univ Penn, Sch Med, Dept Pathol, Stellar Chance Labs, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Internal Med, Stellar Chance Labs, Philadelphia, PA 19104 USA
来源
CRITICAL REVIEWS IN ONCOGENESIS | 1997年 / 8卷 / 01期
关键词
oligodeoxynucleotide; antisense; ribozyme; CML; bcr/abl; leukemia; c-myb; c-kit; vav; hematopoiesis;
D O I
10.1615/CritRevOncog.v8.i1.50
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of reliable gene disruption strategies, and their application in living cells, has proven to be an extraordinarily important advance for cell and molecular biologists. Using the various available approaches, the specific functions of any given gene may now be investigated directly in the relevant cell type. Application of similar experimental tools in a clinical setting might prove to be equally valuable and could well form the basis of a monumental advance in the practice of clinical medicine. This seems particularly true at the present time since much progress has been made in understanding the molecular pathogenesis of many diseases, including cancer. For these reasons a tremendous amount of interest has been generated in the use of oligodeoxynucleotides to modify gene expression. However, in spite of some notable successes which are detailed in this review, oligonucleotides have generated controversy in regards to their mechanism of action, reliability, and ultimate therapeutic utility. Nevertheless, the potential power of the "antisense" approach remains undisputed, and its ultimate therapeutic utility is far reaching. Accordingly, the problems associated with the use of these compounds are clearly worth solving. It remains the hope of many laboratories that the day will soon come when these techniques will make an important contribution to the management of CML and other neoplastic disorders.
引用
收藏
页码:93 / 109
页数:17
相关论文
共 134 条
[1]  
ADAMS JM, 1992, ONCOGENE, V7, P611
[2]  
ALAI M, 1992, J BIOL CHEM, V267, P18021
[3]  
Algar EM, 1996, ONCOGENE, V12, P1005
[4]  
Anderegg B, 1997, CANCER GENE THER, V4, P84
[5]   AN OLIGOMER COMPLEMENTARY TO C-MYB-ENCODED MESSENGER-RNA INHIBITS PROLIFERATION OF HUMAN MYELOID-LEUKEMIA CELL-LINES [J].
ANFOSSI, G ;
GEWIRTZ, AM ;
CALABRETTA, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (09) :3379-3383
[6]  
ARSURA M, 1992, BLOOD, V79, P2708
[7]  
BACON TA, 1991, ONCOGENE RES, V6, P21
[8]   INTERLEUKIN-6 FUNCTIONS AS AN INTRACELLULAR GROWTH-FACTOR IN HAIRY-CELL LEUKEMIA IN-VITRO [J].
BARUT, B ;
CHAUHAN, D ;
UCHIYAMA, H ;
ANDERSON, KC .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (05) :2346-2352
[9]   RNA STRUCTURE - DESCRIBING THE ELEPHANT [J].
BASKERVILLE, S ;
ELLINGTON, AD .
CURRENT BIOLOGY, 1995, 5 (02) :120-123
[10]  
Bayever E, 1993, Antisense Res Dev, V3, P383